Obesity drug maker Sciwind targets IPO, with heavyweight backers 騰訊美團押注減肥藥明星企業 先為達生物沖刺港股
Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition 核心產品埃諾格魯肽注射液預計將于2026年正式獲批上市，公司已處于商業化前夕。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.